Supernus Pharmaceuticals | SUPN - Current Assets


Supernus Pharmaceuticals reported $723.5M in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
Abbott USD 25.51B 488M Mar/2026
ANI Pharmaceuticals USD 747.08M 6.03M Mar/2026
Aurora Cannabis CAD 397.45M 48.38M Mar/2026
Bristol-Myers Squibb USD 28.58B 1.37B Jun/2026
Canopy Growth CAD 529.47M 4.8M Mar/2026
Cara Therapeutics USD 25.33M 6.21M Mar/2026
Corcept Therapeutics USD 439.68M 13.64M Jun/2026
Eisai JPY 883.01B 121.38B Jun/2026
Eli Lilly USD 64.67B 9.84B Jun/2026
Novo Nordisk DKK 208.7B 31.38B Jun/2026
Pacira USD 615.21M 100.25M Jun/2026
Perrigo USD 2.45B 260.7M Jun/2026
Pfizer USD 41.36B 1.46B Jun/2026
Supernus Pharmaceuticals USD 723.5M 8.08M Jun/2026
United Therapeutics USD 3.48B 611.7M Jun/2026
Xeris Pharmaceuticals USD 251.68M 11.37M Mar/2026